ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory

Grant

Total Award Amount

  • 22900.00
  • Direct Costs

  • 16838.00
  • Sponsor Award Id

  • Contributor

  • Ana Galtarossa Xavier   Investigator  
  • Elizabeth Alva   Investigator  
  • Emily Johnston   Investigator  
  • Gregory Friedman M.D.   Principal Investigator  
  • Jamie Aye   Investigator  
  • Kimberly Whelan M.D.   Investigator  
  • Laura Metrock   Investigator  
  • Matthew Kutny M.D.   Investigator